Azam M - Search Results

1

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Zhang J, et al. Among authors: azam m. Nature. 2010 Jan 28;463(7280):501-6. doi: 10.1038/nature08675. Epub 2010 Jan 13. Nature. 2010. PMID: 20072125 Free PMC article.

2

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Weisberg E, et al. Among authors: azam m. Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007. Cancer Cell. 2005. PMID: 15710326 Free article.

3

Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.

Azam M, Daley GQ. Azam M, et al. Mol Diagn Ther. 2006;10(2):67-76. doi: 10.1007/BF03256446. Mol Diagn Ther. 2006. PMID: 16669605 Review.

4

Activation of tyrosine kinases by mutation of the gatekeeper threonine.

Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Azam M, et al. Nat Struct Mol Biol. 2008 Oct;15(10):1109-18. doi: 10.1038/nsmb.1486. Epub 2008 Sep 14. Nat Struct Mol Biol. 2008. PMID: 18794843 Free PMC article.

5

AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.

Azam M, Powers JT, Einhorn W, Huang WS, Shakespeare WC, Zhu X, Dalgarno D, Clackson T, Sawyer TK, Daley GQ. Azam M, et al. Chem Biol Drug Des. 2010 Feb;75(2):223-7. doi: 10.1111/j.1747-0285.2009.00911.x. Epub 2009 Dec 17. Chem Biol Drug Des. 2010. PMID: 20028401

6

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Azam M, Latek RR, Daley GQ. Azam M, et al. Cell. 2003 Mar 21;112(6):831-43. doi: 10.1016/s0092-8674(03)00190-9. Cell. 2003. PMID: 12654249 Free article.

7

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ. Nardi V, et al. Among authors: azam m. Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006. Curr Opin Hematol. 2004. PMID: 14676625 Review.

8

Farnesyl transferase inhibitor resistance probed by target mutagenesis.

Raz T, Nardi V, Azam M, Cortes J, Daley GQ. Raz T, et al. Among authors: azam m. Blood. 2007 Sep 15;110(6):2102-9. doi: 10.1182/blood-2006-12-064907. Epub 2007 May 29. Blood. 2007. PMID: 17536018 Free PMC article.

9

ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Nardi V, Naveiras O, Azam M, Daley GQ. Nardi V, et al. Among authors: azam m. Blood. 2009 Apr 16;113(16):3813-20. doi: 10.1182/blood-2008-07-167189. Epub 2009 Jan 26. Blood. 2009. PMID: 19171873 Free PMC article.

10

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Azam M, et al. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

887 results

Search Page